We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against other top stocks to buy according to 12 West Capital Management.
Joel Ramin founded 12 West Capital Management in August 2011, establishing it as a New York-based hedge fund specializing in global investments across equities, equity-related instruments, and credit securities. Prior to launching 12 West, Ramin worked as an analyst at Bridger Capital, gaining experience in both long equity positions and short-selling strategies. Currently, he serves as the firm’s Managing Member and Portfolio Manager, overseeing investment decisions and advisory services for institutional investors in the United States.
12 West Capital Management focuses on providing tailored investment management solutions, leveraging a research-driven approach to identify opportunities across various markets. The firm actively engages in both long-term and short-term investments, aiming to maximize returns through strategic asset allocation and risk management. Its expertise spans multiple asset classes, allowing it to adapt to changing market conditions while delivering value to its clients.
Joel Ramin holds a degree from the McIntire School of Commerce, where he completed his undergraduate studies in finance in 2000. His background in finance and investment, combined with his experience at Bridger Capital, has shaped his approach to portfolio management at 12 West Capital. Under his leadership, the firm has built a reputation for its disciplined investment strategies and commitment to generating long-term growth for its investors.
According to its most recent 13F filing for the fourth quarter of 2024, 12 West Capital Management reported nearly $954.6 million in managed 13F securities, with its top 10 holdings accounting for a hefty 90.75% of its portfolio.
Our Methodology
The stocks discussed below were picked from 12 West Capital Management’s Q4 2024 13F filings. They are compiled in the ascending order of the hedge fund’s stake in them as of December 31, 2024. To assist readers with more context, we have included the hedge fund sentiment regarding each stock using data from 1009 hedge funds tracked by Insider Monkey in the fourth quarter of 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A researcher in a laboratory coat working with laboratory equipment for nucleic acids.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Number of Hedge Fund Holders as of Q4: 25
12 West Capital Management’s Equity Stake: $63.17 Million
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) specializes in providing essential products that support the development of drug therapies, novel vaccines, and diagnostics, while also advancing research on human diseases through proprietary technologies. Its client portfolio includes leading companies such as TriLink Biotechnologies, Glen Research, Cygnus Technologies, and Vector Laboratories, with expertise in biologics safety testing, nucleic acid production, and protein detection. Based in San Diego, California, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) plays a critical role in the life sciences sector.
On March 18, 2025, the company released its financial results for Q4 2024 and the full year. CEO Trey Martin acknowledged that while the fourth-quarter revenue was within the projected range, challenges arose due to economic uncertainties and shifting customer spending priorities. However, he highlighted the company’s progress, including facility expansions, new product launches, and strategic acquisitions, which have reinforced Maravai’s long-term growth strategy. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) remains committed to leveraging its unique technologies to support clients from early-stage discovery through commercialization.
The company’s fourth-quarter revenue totaled $56.6 million, marking a 23.7% year-over-year decline. Nucleic Acid Production revenue dropped 28.8% to $41.9 million, primarily due to the absence of large GMP orders seen in 2023 and weaker demand for research-related products. Biologics Safety Testing revenue fell 4.3% to $14.7 million, reflecting reduced bioprocessing market demand. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) reported a net loss of $46.1 million and an adjusted EBITDA loss of $1.1 million, compared to a net loss of $110 million and adjusted EBITDA of $20.5 million in Q4 2023.
For the full year 2024, revenue declined 10.3% to $259.2 million. Nucleic Acid Production revenue was $196.3 million, down 12.6% due to decreased demand for research and discovery products. Biologics Safety Testing revenue slipped 2.1% to $62.8 million, mainly attributed to weaker demand in China’s bioprocessing sector. The company posted a net loss of $259.6 million and adjusted EBITDA of $35.9 million, compared to a net loss of $138.4 million and adjusted EBITDA of $65.3 million in 2023. Despite these financial headwinds, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) continues to focus on strategic initiatives aimed at driving future growth.
Overall, MRVI ranks 5th on our list of top stocks to buy according to 12 West Capital Management. While we acknowledge the potential for MRVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRVI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
